Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

All participants will receive a single dose of their assigned vaccine on Day 0. A subset of the participants will be assessed for immunologic response on Day 0 before vaccination and Day 28 after vaccination. All subjects will be monitored for safety for up to 6 months after vaccination.